ROH-202

ROH-202 is an investigational ophthalmic therapeutic agent being developed by Rohto Pharmaceutical Co., Ltd., a Japanese multinational corporation specializing in eye care and pharmaceuticals. As of early 2024, the drug is in Phase 1 clinical development in Japan for the treatment of unspecified ophthalmic conditions. Rohto Pharmaceutical, which holds a significant share of the Japanese over-the-counter eye-drop market, has not yet publicly disclosed the specific molecular target, biological mechanism of action, or modality (such as small molecule or biologic) for ROH-202. The candidate is part of the company's strategic expansion into the prescription ophthalmology sector, alongside other pipeline assets like the JAK inhibitor ROH-201.